A retrospective study to evaluate efficacy, safety and economic impact of dual therapy with dolutegravir plus darunavir/cobicistat as salvage therapy regimen in patients with HIV-1 infection

Trial Profile

A retrospective study to evaluate efficacy, safety and economic impact of dual therapy with dolutegravir plus darunavir/cobicistat as salvage therapy regimen in patients with HIV-1 infection

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 New trial record
    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top